Ocrelizumab Demonstrates Near-Complete Suppression of Relapses for Multiple Sclerosis

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

Related Keywords

United States ,Colorado ,American ,Ocrelizumab Ocrevus ,Levi Garraway ,Scott Newsome ,Johns Hopkins University School Of Medicine ,National Multiple Sclerosis Society ,Global Product Development At Roche ,American Academy ,Neurology Annual Meeting ,Global Product Development ,Johns Hopkins University School ,